7Baggers
 Vistagen (VTGN) Q2 2026 Earnings Call Transcript  The Motley Fool Fri, 14 Nov 2025 18:10:00 GMT
 Earnings call transcript: VistaGen Q2 2025 reveals strategic progress By Investing.com  Investing.com South Africa Fri, 14 Nov 2025 06:26:02 GMT
 Vistagen Therapeutics Reports Q2 2026 Financial Results  TipRanks Fri, 14 Nov 2025 04:14:17 GMT
 VistaGen Bets On Big Trials Despite Growing Losses  Finimize Fri, 14 Nov 2025 03:42:59 GMT
 VistaGen Bets Big On Social Anxiety Drug With Rising Losses  Finimize Fri, 14 Nov 2025 02:35:53 GMT
 Vistagen reports Q2 EPS (54c), consensus (44c)  TipRanks Thu, 13 Nov 2025 22:23:20 GMT
 Vistagen (VTGN) Surpasses Q2 Revenue Expectations and Advances K  GuruFocus Thu, 13 Nov 2025 22:05:47 GMT
 Biopharmaceutical firm Vistagen's fiscal Q2 net loss widens  MarketScreener Thu, 13 Nov 2025 21:58:21 GMT
 VistaGen at Stifel Conference: Strategic Insights on Anxiety Treatment  Investing.com Thu, 13 Nov 2025 00:38:32 GMT
 vistagen at stifel conference: strategic insights on anxiety treatment  Investing.com India Wed, 12 Nov 2025 22:46:25 GMT
 vistagen therapeutics q2 2026 earnings preview  MSN Wed, 12 Nov 2025 16:35:03 GMT
 What To Expect From Vistagen Therapeutics Inc (VTGN) Q2 2026 Ear  GuruFocus Wed, 12 Nov 2025 12:43:49 GMT
 mental disorder treatment market poised for boom with key  openPR.com Thu, 06 Nov 2025 10:49:37 GMT
 vistagen to participate in stifel healthcare conference 2025  Yahoo Finance Wed, 05 Nov 2025 08:00:00 GMT
 published on: 2025-11-04 05:24:21  newser.com Tue, 04 Nov 2025 11:24:21 GMT
 VistaGen Completes Patient Phase in Key Clinical Trial  TipRanks Tue, 04 Nov 2025 08:00:00 GMT
 vistagen completes portion of palisade-3 trial  TipRanks Mon, 03 Nov 2025 14:39:16 GMT
 VistaGen stock rises after completing Phase 3 trial for anxiety drug  Investing.com Mon, 03 Nov 2025 08:00:00 GMT
 vistagen completes primary phase of fasedienol social anxiety trial  Investing.com Mon, 03 Nov 2025 08:00:00 GMT
 published on: 2025-11-01 04:45:37  newser.com Sat, 01 Nov 2025 09:45:37 GMT

VistaGen Therapeutics, Inc
(NASDAQ:VTGN) 

VTGN stock logo

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset n...

Full Time Employees: 9
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends